TriangleAbemaciclib (NCT07191717)
Abemaciclib trial for Anatomic Stage I Breast Cancer AJCC v8 (NCT07191717). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with removed stage I–III, estrogen-receptor-positive, HER2-negative breast cancer, positive tumor-DNA testing, and no clinical or imaging evidence of recurrence. At least two years of endocrine treatment are required.
The idea: oral imlunestrant degrades estrogen receptors; twice-daily oral abemaciclib blocks CDK4/6 proteins involved in cell division. Treatment lasts up to twelve 28-day cycles. Researchers check whether circulating tumor DNA clears. This result does not establish that recurrence is prevented.
This phase 2 study plans 42 patients. Marla Lipsyc-Sharf leads at UCLA in Los Angeles, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.